Market Access & Reimbursement
Avania Fireside Chat • Live Panel + Q&A | Wednesday, September 9, 2026 • 1:00 PM ET / 10:00 AM PT
The LDT rule is gone, the reporting window that sets your 2027 Medicare rates has closed, and AI is on every panel. Two Avania IVD experts on what actually changed in 2026 and what it means for your next study.
IVD 2026: What Changed, and What You Still Have to Do
2026 has been the most consequential year for US diagnostics in a decade, and the two developments that defined it...
The Payment Gap in Molecular Imaging Just Changed. Is Your Coding and Coverage Strategy Keeping Up?
Get Your Copy Now Name(Required) First Name Last Name Company name(Required)Email(Required) Consent(Required) By checking here, you agree for the information...
Radiopharmaceutical Reimbursement in 2026, Approved but Not Yet Paid
The Food and Drug Administration (FDA) approved your diagnostic radiopharmaceutical. Now try to get a hospital to use it. For...
The Future of MedTech Trials
US Market Access: Optimizing MedTech Reimbursement Strategies
Get Your Copy Now U.S. healthcare system includes thousands of payers with varying coverage policies —making market access one of...
Advancing Your Medical Technology with Avania
Get Your Copy Now Name(Required) First Name Last Name Company name(Required)Email(Required) Consent(Required) By checking here, you agree for the information...
Global Strategies for Digital Health Reimbursement
Get Your Copy Now Name(Required) First Name Last Name Company name(Required)Email(Required) Consent(Required) By checking here, you agree for the information...